Navigation Links
ChartTrends®: Multiple Sclerosis Report Reveals the Latest Approach to the Treatment and Management of MS
Date:11/2/2010

EXTON, Pa., Nov. 2, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US. ChartTrends®: Multiple Sclerosis is an annual publication based on patient level data collected on 1,000 MS patients being treated with disease modifying agents (DMAs).

In addition to helping to define the DMA-treated MS patient (demographics, co-morbidities, concomitant medications, prevalence of symptoms and symptomatic treatment), the report provides insight into the factors that drive decisions to initiate treatment and factors that drive DMA brand selection for both first line and switch patients. Profiles for patients treated with each DMA brand (Avonex, Betaseron, Copaxone, Rebif and Tysabri) are provided. There are a number of differences between patients treated with the various DMAs including MRI status, functioning, disease progression, clinical response and likelihood of switching to a pipeline DMA in the future. The most likely patient types for newly approved Gilenya and late-stage DMAs in development (e.g. Movectro, alemtuzumab, daclizumab) are identified. A number of patient characteristics, including disease classification and current DMA brand, influence the likelihood of a potential switch to Gilenya.

Since initiating on their most current DMA, one-third of patients have experienced an exacerbation with the most common symptoms including muscle weakness and gait/coordination issues. While most exacerbations are treated with short steroid pulses, the use of chronic pharmacological treatment is common for management of spasticity, pain syndromes, bladder/bowel dysfunction, depression/apathy and fatigue. The patient types being selected for treatment with Ampyra, the first FDA-approved symptomatic agent for MS launched in March 2010, are identified in the report.

About BioTrends Research Group, Inc.BioTrends Research Group,
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Orthopedic Market Research Data Covering Multiple Geographies Released by Millennium Research Group
2. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
3. ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients
4. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
5. Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
6. Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
7. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
8. Reportlinker Adds Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets
9. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
10. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
11. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  A new analysis of Centers for ... enrollment data shows that 81 percent of seniors chose ... extra discounts at certain pharmacies. The findings were released ... plans are now the foundation of Medicare Part D," ...
(Date:1/23/2015)... ORLANDO, Fla. and DUBLIN , ... of the agreement with KRS Global Biotechnology, Inc. for the ... will be compounded for shipment in the United ... 503B FDA approved Outsourcing Facility capable of compounding naltrexone tablets ...
(Date:1/23/2015)... available for sale, The Armor1 Ankle Roll Guard is a ... by cushioning the ankle from an inversion or "roll." ... of any shoe type and allows the user to ... against sprains. With customers in physical therapy, podiatry, and ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... ThermoGenesis Corp. (Nasdaq: KOOL ), a leading supplier ... stem cells, reported results for the second quarter of fiscal ... the Company reported revenues of $5.9 million, which compares with ... ago. Disposable revenues in the second quarter of fiscal 2011 ...
... 10, 2011 Cambrex Corporation (NYSE: CBM ) reports ... 31, 2010. Highlights ... currency, sales increased 9.2% compared to fourth quarter 2009. Adjusted ... of 54% compared to $9.4 million of EBITDA in the fourth ...
Cached Medicine Technology:ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 2ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 3ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 4ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 5ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 6ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 7Cambrex Reports Fourth Quarter and Full Year 2010 Results 2Cambrex Reports Fourth Quarter and Full Year 2010 Results 3Cambrex Reports Fourth Quarter and Full Year 2010 Results 4Cambrex Reports Fourth Quarter and Full Year 2010 Results 5Cambrex Reports Fourth Quarter and Full Year 2010 Results 6Cambrex Reports Fourth Quarter and Full Year 2010 Results 7Cambrex Reports Fourth Quarter and Full Year 2010 Results 8Cambrex Reports Fourth Quarter and Full Year 2010 Results 9
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the main ... , Auto insurance quotes help many drivers find the ... to call an agent or visit an agency for price ... website: http://autocarinsurancebest.com/ . , Every business who relies heavily ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... analytics, and clinical business intelligence solutions today announced that it is working with Oracle to further the goals of improving quality of care reporting and patient safety ... ... ... ...
... ... that builds open source platforms and develops advanced research solutions, has ... totaling more than $600,000 to focus research efforts on developing approach-specific, ... is to work towards an interactive simulator that replicates future neurosurgery ...
... BOSTON Improving on traditional screening tests for potential ... developed a laboratory technique that more closely simulates ... with the body,s normal cells. Because these neighboring ... as the "tumor microenvironment" can alter the ...
... exam, study finds , SUNDAY, March 14 (HealthDay News) -- ... and collegiate hockey players in a U.S. study had abnormal ... see if abnormal MRI results are found incidentally in active ... the department of family medicine and orthopedics at Hershey Medical ...
... below currently recommended levels did not significantly ... disease events in adults with type 2 diabetes who ... according to new results from the landmark Action to ... treating multiple blood lipids with combination drug therapy of ...
... NEW YORK, NY AND ATLANTA, GA MARCH 13, ... EXCEL (Evaluation of Xience Prime versus Coronary Artery Bypass ... compare drug-eluting stents to coronary artery bypass graft surgery ... made today at "Optimizing PCI Outcomes: Evolving Paradigms," a ...
Cached Medicine News:Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 2Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 3Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 4Health News:National Institutes of Health Awards Kitware Over $600,000 to Develop Advancements in Neurosurgical Simulation 2Health News:National Institutes of Health Awards Kitware Over $600,000 to Develop Advancements in Neurosurgical Simulation 3Health News:New cancer drug screening technique more closely mirrors reality 2Health News:New cancer drug screening technique more closely mirrors reality 3Health News:Scans May Be Misleading for Hockey Players 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 3Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 4Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 5Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 6Health News:EXCEL trial will determine safety and efficacy of drug-eluting stents vs. bypass surgery 2
... The RSV ASR contains primers and a ... Respiratory Syncytial Virus (RSV). In addition, this ... probe for a,separate sample processing control. This ... FAM and Texas Red reporter dyes such ...
Digital Ultrasonic Diagnostic Imaging System...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Pefakit PiCT LMWH Controls...
Medicine Products: